- Home
- FBRX vs ANIK Comparison
FBRX vs ANIK Comparison
Compare FBRX & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- ANIK
- Stock Information
- Founded
- FBRX N/A
- ANIK 1983
- Country
- FBRX United States
- ANIK United States
- Employees
- FBRX N/A
- ANIK N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- ANIK Medical/Dental Instruments
- Sector
- FBRX Health Care
- ANIK Health Care
- Exchange
- FBRX Nasdaq
- ANIK Nasdaq
- Market Cap
- FBRX 154.5M
- ANIK 133.1M
- IPO Year
- FBRX N/A
- ANIK 1993
- Fundamental
- Price
- FBRX $10.92
- ANIK $8.94
- Analyst Decision
- FBRX Strong Buy
- ANIK Buy
- Analyst Count
- FBRX 3
- ANIK 1
- Target Price
- FBRX $68.00
- ANIK $15.00
- AVG Volume (30 Days)
- FBRX 63.8K
- ANIK 113.7K
- Earning Date
- FBRX 08-14-2025
- ANIK 10-30-2025
- Dividend Yield
- FBRX N/A
- ANIK N/A
- EPS Growth
- FBRX N/A
- ANIK N/A
- EPS
- FBRX N/A
- ANIK N/A
- Revenue
- FBRX N/A
- ANIK $114,548,000.00
- Revenue This Year
- FBRX N/A
- ANIK N/A
- Revenue Next Year
- FBRX N/A
- ANIK $5.33
- P/E Ratio
- FBRX N/A
- ANIK N/A
- Revenue Growth
- FBRX N/A
- ANIK 16.52
- 52 Week Low
- FBRX $4.11
- ANIK $7.87
- 52 Week High
- FBRX $28.68
- ANIK $26.00
- Technical
- Relative Strength Index (RSI)
- FBRX 48.35
- ANIK 45.51
- Support Level
- FBRX $10.65
- ANIK $8.91
- Resistance Level
- FBRX $11.57
- ANIK $9.45
- Average True Range (ATR)
- FBRX 0.93
- ANIK 0.48
- MACD
- FBRX -0.04
- ANIK 0.07
- Stochastic Oscillator
- FBRX 19.22
- ANIK 44.72
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.